FDA Approves First Quadrivalent Flu Vaccine
- By BSTQ Staff
The U.S. Food and Drug Administration has approved the first vaccine that protects against four strains of the common flu, offering one additional layer of protection against the influenza virus. The FluMist Quadrivalent vaccine from AstraZeneca’s MedImmune unit protects against two strains of influenza A and two strains of influenza B. The spray-based vaccine, which delivers weakened strains of the virus, is approved for people ages 2 to 49. All other flu vaccines on the market are trivalent vaccines, which contain two strains of influenza A and one strain of influenza B.